Crossmark

Comparison of Reporting Quality in National Cystic Fibrosis Patient Registries: Implications for Identifying Use of Novel CFTR Modulators

Published Online: 2024-09-27

Published Print: 2024-12

Authors

Tomlinson, Owen W. https://orcid.org/0000-0003-4063-7682
Mitchelmore, Philip

Williams, Craig A.
License Information

Text and Data Mining valid from 2024-09-27

Version of Record valid from 2024-09-27
More Information

Article History

Received: 29 June 2024

Accepted: 16 September 2024

First Online: 27 September 2024

Declarations

:

: Owen W Tomlinson reports conference fees from Chiesi Ltd., and speaker fees from Vertex Pharmaceuticals. Philip Mitchelmore reports no conflicts of interest. Craig A Williams reports no conflicts of interest.

: No ethical approval was required for this study, as it is a secondary analysis of publicly available data. References to the included databases are included within the reference list.

: No medical writing or editorial assistance (including the use of generative AI) was received during the course of writing this article.

: For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY-NC) licence to any Author Accepted Manuscript version arising from this submission.

Document is current